ERBB3 and neoplasm: Trastuzumab deruxetecan, an anti-HER2 antibody drug conjugate, and patritumab deruxetecan, an anti-HER3 antibody drug conjugate, have been shown to be effective against NSCLC and are taken into cells by binding to HER2 or HER3 expressed on the cell membrane of tumor cells, and once the linker is hydrolyzed, When the linker is hydrolyzed, camptothecin derivatives and U3-1402 are released, causing DNA damage and inducing apoptosis, thereby exerting an antitumor effect.